OTCPK:OMRX

Stock Analysis Report

Executive Summary

Orthometrix, Inc. develops technologies, procedures, and devices to help increase musculoskeletal mobility, as well as non-invasive technologies to treat the pain associated with osteoarthritis, plantar fasciitis, and other musculoskeletal conditions that reduce mobility.

Snowflake

Fundamentals

Adequate balance sheet with weak fundamentals.

Risks

  • Orthometrix has significant price volatility in the past 3 months.
  • Orthometrix's last earnings update was 3972 days ago.
  • Orthometrix is not covered by any analysts.

Similar Companies

Share Price & News

How has Orthometrix's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

OMRX

0.7%

US Medical Equipment

-0.2%

US Market


1 Year Return

n/a

OMRX

9.5%

US Medical Equipment

1.1%

US Market

No trading data on OMRX.

No trading data on OMRX.


Share holder returns

OMRXIndustryMarket
7 Day0%0.7%-0.2%
30 Day0%0.1%2.5%
90 Dayn/a2.5%1.6%
1 Yearn/a10.4%9.5%3.4%1.1%
3 Year-72.4%-72.4%69.3%64.1%45.2%35.8%
5 Year-95.8%-95.8%138.0%110.9%62.6%44.8%

Price Volatility Vs. Market

How volatile is Orthometrix's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Orthometrix undervalued based on future cash flows and its price relative to the stock market?


In this section, we usually try to help investors determine whether Orthometrix is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Orthometrix has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Examine Orthometrix's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Orthometrix regulatory filings here.
  • Explore potentially undervalued companies in the Healthcare industry.

Future Growth

How is Orthometrix expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

22.5%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Orthometrix has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Orthometrix performed over the past 5 years?

0.2%

Historical Healthcare annual earnings growth


In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, Orthometrix has not provided sufficient past data to assess its track record.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data.


Next Steps

Financial Health

How is Orthometrix's financial position?


In this section we usually analyse Orthometrix's finance health to determine how well-positioned it is against times of financial distress, in particular, its ability to manage its cash and debt levels. Orthometrix has not provided adequate balance sheet data, its financial health cannot be properly assessed as it.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have financial information.


Next Steps

  • Take a look at our analysis of OMRX’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • Investors tend to look at the financial health of a company this size in order to assess the sustainability of its current operations. While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website.
  • Financial health is measured at one point in time, so the latest financial report is the best representation of the company’s current financial status. Check when Orthometrix's financial data was last updated here.
  • Explore more healthy companies in the Healthcare industry.

Dividend

What is Orthometrix's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Orthometrix's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Orthometrix's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Orthometrix has not reported any payouts.

Unable to verify if Orthometrix's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Orthometrix has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Orthometrix's salary, the management and board of directors tenure and is there insider trading?

US$2k

CEO Compensation


CEO

Reynald Bonmati (71yo)

0yrs

Tenure

US$1,701

Compensation

Mr. Reynald G. Bonmati, M.Sc. Ch.E., MBA serves as a Founder, Chief Executive Officer, President and Treasurer, of Orthometrix, Inc. Mr. Bonmati has been the Chief Executive Officer and the Chairman of And ...


Insider Trading

No 3 month open market individual insider trading information.


Management Team

  • Reynald Bonmati (71yo)

    Founder

    • Tenure: 0yrs
    • Compensation: US$1.70k
  • Arik Avni (59yo)

    Chief Technical Officer

    • Tenure: 6yrs

Board Members

  • Reynald Bonmati (71yo)

    Founder

    • Tenure: 0yrs
    • Compensation: US$1.70k
  • André-Jacques Neusy (75yo)

    Director

    • Tenure: 17.4yrs

Company Information

Orthometrix, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Orthometrix, Inc.
  • Ticker: OMRX
  • Exchange: OTCPK
  • Founded: 1993
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$122.387k
  • Shares outstanding: 53.21m
  • Website: https://null

Location

  • Orthometrix, Inc.
  • 5621 Strand Boulevard
  • Suite 111
  • Naples
  • Florida
  • 34110
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
OMRXOTCPK (Pink Sheets LLC)YesCommon StockUSUSDAug 1995

Biography

Orthometrix, Inc. develops technologies, procedures, and devices to help increase musculoskeletal mobility, as well as non-invasive technologies to treat the pain associated with osteoarthritis, plantar fa ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/20 00:18
End of Day Share Price2019/09/17 00:00
Earnings2008/09/30
Annual Earnings2007/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.